Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9020671 | 0.62 | — | — | |
| SCHEMBL83401 | 0.62 | — | — | |
| SCHEMBL3627241 | 0.62 | ADORA2A (0.39) | HTTTRPV1SMN1; SMN2KDM4E | |
| SCHEMBL1768141 | 0.61 | HTT (0.34) | HTTTRPV1 | |
| SCHEMBL10320121 | 0.60 | HTT (0.46) | HTTTRPV1MAPTTP53LMNA | |
| SCHEMBL8832754 | 0.58 | — | — | |
| SCHEMBL179568 | 0.57 | — | — | |
| SCHEMBL29919713 | 0.57 | — | — | |
| SCHEMBL4502152 | 0.57 | P2RX7 (0.38) | HTTTRPV1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL859422 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC | 2012-11-22 | — | — | US | disclosed |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC | 2012-11-22 | — | — | US | disclosed |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC | 2012-11-22 | — | — | US | disclosed |
| EP-2504342-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | Pfizer Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011061679-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061679-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | GPR3, GPR119, GPR84 | HTT 1942/4885TRPV1 320/4885MAPT 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.